Your browser doesn't support javascript.
loading
High-throughput approaches to uncover synergistic drug combinations in leukemia.
Chory, Emma J; Wang, Meng; Ceribelli, Michele; Michalowska, Aleksandra M; Golas, Stefan; Beck, Erin; Klumpp-Thomas, Carleen; Chen, Lu; McKnight, Crystal; Itkin, Zina; Wilson, Kelli M; Holland, David; Divakaran, Sanjay; Bradner, James; Khan, Javed; Gryder, Berkley E; Thomas, Craig J; Stanton, Benjamin Z.
Afiliação
  • Chory EJ; Media Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute o
  • Wang M; Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, Columbus, OH, USA.
  • Ceribelli M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Michalowska AM; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Golas S; Media Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Beck E; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Klumpp-Thomas C; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Chen L; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • McKnight C; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Itkin Z; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Wilson KM; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Holland D; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.
  • Divakaran S; Cardio-Oncology Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bradner J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Khan J; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Gryder BE; Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio 44106, United States.
  • Thomas CJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA.; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Stanton BZ; Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, Columbus, OH, USA.; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA; Department of Biological Chemistry & Pharmacology, The Ohio State University College of Medicine, Columb
SLAS Discov ; 28(4): 193-201, 2023 06.
Article em En | MEDLINE | ID: mdl-37121274
ABSTRACT
We report a comprehensive drug synergy study in acute myeloid leukemia (AML). In this work, we investigate a panel of cell lines spanning both MLL-rearranged and non-rearranged subtypes. The work comprises a resource for the community, with many synergistic drug combinations that could not have been predicted a priori, and open source code for automation and analyses. We base our definitions of drug synergy on the Chou-Talalay method, which is useful for visualizations of synergy experiments in isobolograms, and median-effects plots, among other representations. Our key findings include drug synergies affecting the chromatin state, specifically in the context of regulation of the modification state of histone H3 lysine-27. We report open source high throughput methodology such that multidimensional drug screening can be accomplished with equipment that is accessible to most laboratories. This study will enable preclinical investigation of new drug combinations in a lethal blood cancer, with data analysis and automation workflows freely available to the community.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: SLAS Discov Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: SLAS Discov Ano de publicação: 2023 Tipo de documento: Article